A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Clinical trial NCT06769113 · RECRUITING
Trial details
- NCT number
- NCT06769113
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-26
- Primary completion
- 2026-10-31
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.